VNRX
VolitionRx Limited
Medical - Diagnostics & Research
Market Cap$13M
5Y Perf.-96.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VNRX vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$31.16B
5Y Perf.+401.3%
VNRX vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VNRX | NTRA |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $13M | $31.16B |
| Revenue (TTM) | $2M | $2.31B |
| Net Income (TTM) | $-23M | $-208M |
| Gross Margin | 100.0% | 64.8% |
| Operating Margin | -12.5% | -13.4% |
| Total Debt | $11M | $214M |
| Cash & Equiv. | $1M | $1.08B |
VNRX vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VNRX
NTRA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| VolitionRx Limited (VNRX) | 100 | 3.9 | -96.1% |
| Natera, Inc. (NTRA) | 100 | 501.3 | +401.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VNRX vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NTRA leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. VolitionRx Limited is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
VNRX
VolitionRx Limited
The Income Pick
VNRX is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.17
- Rev growth 40.0%, EPS growth 29.0%, 3Y rev CAGR 78.0%
- Lower volatility, beta 0.17, current ratio 0.17x
Best for: income & stability and growth exposure
NTRA
Natera, Inc.
The Long-Run Compounder
NTRA carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 20.9% 10Y total return vs VNRX's -96.2%
- -9.0% margin vs VNRX's -13.5%
- +37.3% vs VNRX's -76.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNRX | 40.0% revenue growth vs NTRA's 35.9% |
| Quality / Margins | NTRA | -9.0% margin vs VNRX's -13.5% |
| Stability / Safety | VNRX | Beta 0.17 vs NTRA's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NTRA | +37.3% vs VNRX's -76.7% |
| Efficiency (ROA) | NTRA | -10.6% ROA vs VNRX's -305.6% |
VNRX vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
VNRX vs NTRA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNTRALAGGINGVNRX
VNRXVolitionRx Limited
0leads
NTRANatera, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs VNRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NTRA4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NTRA3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NTRA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.3B annually — 1335.0x VNRX's $2M. Profitability is closely matched — net margins range from -9.0% (NTRA) to -13.5% (VNRX). On growth, VNRX holds the edge at +133.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $2M | $2.3B |
| EBITDAEarnings before interest/tax | -$20M | -$310M |
| Net IncomeAfter-tax profit | -$23M | -$208M |
| Free Cash FlowCash after capex | -$20M | $97M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +64.8% |
| Operating MarginEBIT ÷ Revenue | -12.5% | -13.4% |
| Net MarginNet income ÷ Revenue | -13.5% | -9.0% |
| FCF MarginFCF ÷ Revenue | -11.4% | +4.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +133.2% | +39.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.5% | +185.4% |
NTRA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — VNRX and NTRA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| Market CapShares × price | $13M | $31.2B |
| Enterprise ValueMkt cap + debt − cash | $23M | $30.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.55x | -144.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 7.49x | 13.51x |
| Price / BookPrice ÷ Book value/share | — | 17.55x |
| Price / FCFMarket cap ÷ FCF | — | 285.53x |
Evenly matched — VNRX and NTRA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NTRA leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs VNRX's 2/9, reflecting solid financial health.
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | — | -15.3% |
| ROA (TTM)Return on assets | -3.1% | -10.6% |
| ROICReturn on invested capital | — | -36.1% |
| ROCEReturn on capital employed | — | -18.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $10M | -$862M |
| Cash & Equiv.Liquid assets | $1M | $1.1B |
| Total DebtShort + long-term debt | $11M | $214M |
| Interest CoverageEBIT ÷ Interest expense | -8.44x | -25.21x |
NTRA leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $388 for VNRX. Over the past 12 months, NTRA leads with a +37.3% total return vs VNRX's -76.7%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs VNRX's -60.7% — a key indicator of consistent wealth creation.
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -55.7% | -3.9% |
| 1-Year ReturnPast 12 months | -76.7% | +37.3% |
| 3-Year ReturnCumulative with dividends | -94.0% | +314.0% |
| 5-Year ReturnCumulative with dividends | -96.1% | +115.9% |
| 10-Year ReturnCumulative with dividends | -96.2% | +2089.4% |
| CAGR (3Y)Annualised 3-year return | -60.7% | +60.6% |
NTRA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VNRX and NTRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
VNRX is the less volatile stock with a 0.17 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRA currently trades 85.7% from its 52-week high vs VNRX's 12.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.17x | 1.26x |
| 52-Week HighHighest price in past year | $18.80 | $256.36 |
| 52-Week LowLowest price in past year | $0.27 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +12.9% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 714K | 1.3M |
Evenly matched — VNRX and NTRA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VNRXVolitionRx Limited | NTRANatera, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $262.50 |
| # AnalystsCovering analysts | — | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NTRA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallNatera, Inc. (NTRA)Leads 3 of 6 categories
Loading custom metrics...
VNRX vs NTRA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VNRX or NTRA a better buy right now?
For growth investors, VolitionRx Limited (VNRX) is the stronger pick with 40.
0% revenue growth year-over-year, versus 35. 9% for Natera, Inc. (NTRA). Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VNRX or NTRA?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -96. 1% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus VNRX's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VNRX or NTRA?
By beta (market sensitivity over 5 years), VolitionRx Limited (VNRX) is the lower-risk stock at 0.
17β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 621% more volatile than VNRX relative to the S&P 500.
04Which is growing faster — VNRX or NTRA?
By revenue growth (latest reported year), VolitionRx Limited (VNRX) is pulling ahead at 40.
0% versus 35. 9% for Natera, Inc. (NTRA). On earnings-per-share growth, the picture is similar: VolitionRx Limited grew EPS 29. 0% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, VNRX leads at 78. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VNRX or NTRA?
Natera, Inc.
(NTRA) is the more profitable company, earning -9. 0% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 4% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VNRX or NTRA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VNRX or NTRA better for a retirement portfolio?
For long-horizon retirement investors, VolitionRx Limited (VNRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
17)). Both have compounded well over 10 years (VNRX: -96. 2%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VNRX and NTRA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VNRX: 133.2% · NTRA: 39.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.